BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17483358)

  • 41. Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy.
    Leamon CP; Reddy JA; Vlahov IR; Dorton R; Bloomfield A; Vetzel M; Klein PJ; Westrick E; Xu LC; Wang Y
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1151-1160. PubMed ID: 28451831
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors.
    Müller C; Schubiger PA; Schibli R
    Nucl Med Biol; 2007 Aug; 34(6):595-601. PubMed ID: 17707798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice.
    Pourpak A; Meyers RO; Samulitis BK; Sherry Chow HH; Kepler CY; Raymond MA; Hersh E; Dorr RT
    Anticancer Drugs; 2006 Nov; 17(10):1179-84. PubMed ID: 17075317
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice.
    Singh P; Gupta U; Asthana A; Jain NK
    Bioconjug Chem; 2008 Nov; 19(11):2239-52. PubMed ID: 18950215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
    Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Crystalline camptothecin-20(S)-O-propionate hydrate: a novel anticancer agent with strong activity against 19 human tumor xenografts.
    Cao Z; Kozielski A; Liu X; Wang Y; Vardeman D; Giovanella B
    Cancer Res; 2009 Jun; 69(11):4742-9. PubMed ID: 19458069
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selectivity of folate conjugated polymer micelles against different tumor cells.
    Zhao H; Yung LY
    Int J Pharm; 2008 Feb; 349(1-2):256-68. PubMed ID: 17850996
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].
    Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
    Kurtzberg LS; Roth SD; Bagley RG; Rouleau C; Yao M; Crawford JL; Krumbholz RD; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1029-38. PubMed ID: 19277662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
    McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
    Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Harada K; Ferdous T; Itashiki Y; Takii M; Mano T; Mori Y; Ueyama Y
    Anticancer Res; 2009 Apr; 29(4):1263-70. PubMed ID: 19414373
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and in vitro/in vivo evaluation of novel 99mTc(CO)3-folates.
    Müller C; Schubiger PA; Schibli R
    Bioconjug Chem; 2006; 17(3):797-806. PubMed ID: 16704220
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Growth inhibition of K-ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice.
    Umezawa K; Taniguchi T; Toi M; Ohse T; Tsutsumi N; Yamamoto T; Koyano T; Ishizuka M
    Drugs Exp Clin Res; 1996; 22(2):35-40. PubMed ID: 8879977
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Significant enhancement of antitumor activity and bioavailability of intracellular pH-sensitive polymeric micelles by folate conjugation.
    Bae Y; Kataoka K
    J Control Release; 2006 Nov; 116(2):e49-50. PubMed ID: 17718965
    [No Abstract]   [Full Text] [Related]  

  • 59. Improvement of meta-tetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery. synthesis and in vivo delivery studies.
    Gravier J; Schneider R; Frochot C; Bastogne T; Schmitt F; Didelon J; Guillemin F; Barberi-Heyob M
    J Med Chem; 2008 Jul; 51(13):3867-77. PubMed ID: 18553957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.